Our FAQ section provides key insights into B³ Pharma’s mission and technology. Explore the Angiopep PDC Platform, patient journey in brain metastases (BCBM), expert opinions from leading KOLs, and information on leptomeningeal carcinomatosis. Learn more about the market potential of ANG1005, planned label expansion, and how PDCs compare to ADCs. You can also access a curated list of scientific publications showcasing the strength of B³ Pharma.
Would you like to learn more?
Physicians highlight ANG1005 as an innovative approach to deliver paclitaxel across the blood-brain barrier, particularly for brain metastases and glioblastomas where options are scarce. The LRP-1 platform is seen as a key advantage, and paclitaxel is valued as a well-established oncology drug.
Oncologists respond positively to ANG1005, describing it as a “smart” and promising idea. Using paclitaxel, a familiar drug, facilitates clinical adoption and strengthens the project’s credibility.
LC is a severe complication affecting about 120,000 patients annually in the U.S., with incidence rising due to longer survival and improved imaging. It is most often linked to breast, lung, and melanoma cancers, and diagnosis relies on CSF cytology, neurological symptoms, and imaging.
Angiopep PDC enables safe, targeted delivery across the blood-brain barrier via the LRP-1 receptor.
ANG1005 could reach between $350M to $1.05B of projected sales per year. The expected price is $5,000–$7,000 per treatment cycle, with average treatment lasting 8 to 11 cycles.
B³ Pharma plans to expand paclitaxel use to indications such as LC, brain metastases, and glioblastoma. A positive Phase III interim analysis would allow inclusion in NCCN guidelines, driving adoption among clinicians and payers.
Peptide-Drug Conjugates (PDCs) are smaller, simpler, and less costly to produce than Antibody-Drug Conjugates (ADCs). PDCs show better tumor penetration, lower immunogenicity, and reduced toxicity, while ADCs are more complex, expensive, and potentially hepatotoxic.
B³ Pharma relies on a strong scientific foundation, with publications from 2008 to 2025 in leading journals (Nature Reviews, Clinical Cancer Research, British Journal of Pharmacology), validating the Angiopep platform and ANG1005.
